Sermorelin Where to Buy: Matching 3357.9 g/mol in a Vial

Weights first, result second. Anyone can reverse-engineer criteria that produce a preferred winner, so the honest order is to fix the weights while the answer is still unknown.

Price carries 5 % deliberately. A vial that is cheap per milligram and unverified per milligram is not cheap, it is unpriced risk with a number printed next to it. The rate only becomes decision-relevant once the four testing criteria above it are satisfied.

Identity is the criterion buyers skip and the one that is easiest to verify, because the expected values are published and fixed.

Sermorelin is the active N-terminal fragment of human growth hormone-releasing hormone, GHRH(1-29) amide. PubChem CID 16132413 gives the formula as C149H246N44O42S and the molecular weight as 3357.9 g/mol. The sequence printed on lot 38-01260229 resolves to 29 residues with a C-terminal amide, which is the canonical fragment rather than something adjacent to it.

Turn that into arithmetic and it stops being trivia. A 10 mg label at 3357.9 g/mol is 10 mg ÷ 3357.9 mg per mmol, or 2.978 micromoles of compound. The 11.31 mg this lot assayed is 3.368 micromoles, 13.1 % more. Priced with the code at $36.00, that is $12.09 per micromole on the label and $10.69 per micromole on the assay.

Molar figures are the only way to compare across compounds honestly, because a milligram of a 3357.9 g/mol peptide is not the same count of molecules as a milligram of anything heavier or lighter. It is also the check that catches the substitution buyers most fear: a vial of a cheaper secretagogue sold under this name would not produce this mass. Our identity page works through why sermorelin, tesamorelin, ipamorelin and ibutamoren are four different purchases sold as one category.

Applying the weights to the Ascension listing and its published certificate gives a result with a visible hole in it.

That totals 78 out of 100, and the missing 20 sits in one row. The certificate reports purity and quantity, and testing scope is a property of the lot rather than of the seller, so a later lot could close the gap and this score would move. What it cannot do is close by inference. A page that reads 99.79 % and concludes anything about endotoxin has invented the second number from the first.

The 2-point deduction on dispatch is for the ordinary gap between a stated policy and an exercised one, which no document settles in advance.

Most storefronts selling research peptides do not synthesise them. That is not itself a problem, and pretending otherwise would rule out most of the market. What separates a supplier worth buying from a repackager worth avoiding is whether anything ties the powder in the vial to a test.

• A lot code that appears in two places. On the vial and on the certificate. A certificate with no lot code, or a lot code that appears nowhere on the product, documents someone else's material.
• A named laboratory and a named analyst. This one names MZ Biolabs in Tucson, Arizona, and Ken Pendarvis as the analyst. An unnamed "third-party lab" is a claim, not a reference.
• A date that precedes your order. An analysis dated after the batch shipped is describing something you did not receive.
• A method with a peak count. HPLC-UV-MS with 4 detected peaks tells you how the number was produced. A bare percentage does not.

Run those four checks and most of the market falls away without any judgement about vendors as businesses. The checks are about documents, and documents either exist or do not.

Where to buy has an unusual second answer here, and any page that gives only the research-listing answer is leaving out the more legitimate route.

Sermorelin was an approved drug. EMD Serono marketed it as Geref under NDA 019863 for diagnostic use and NDA 020443 for therapeutic use, the second approved on 1997-09-26. Both are discontinued, and the FDA record carries the determination that the product was not discontinued or withdrawn for safety or effectiveness reasons. There is no current US label.

The consequence is procedural rather than sentimental. Under section 503A a compounding pharmacy may use a bulk substance that was a component of an FDA-approved drug product, and sermorelin acetate was exactly that. FDA's Category 2 bulk substances list, which flags substances presenting significant safety risks, names ibutamoren mesylate under both 503A and 503B and names ipamorelin acetate, GHRP-2 and GHRP-6. Sermorelin is absent from the Category 2 list in every one of those sections. So a prescription-based route genuinely exists, which is not true of most research peptides, and our prescription page covers what that route asks for.

Hold both facts at once. The approved indications were paediatric growth hormone deficiency and pituitary diagnostics. PubMed returns 332 records mentioning the compound, 3 with it in the title, and zero when the search adds anti-aging. ClinicalTrials.gov registers no studies naming it. A real regulatory route does not create a literature for the use the modern market advertises.

Price enters last because it is the only criterion that cannot be wrong. $99.99 is the list, $72.00 is the site price and $36.00 applies with the code PEPTIDEDECK. Divided by the 10 mg label those are $10.00, $7.20 and $3.60 per milligram. Divided by the 11.31 mg this lot assayed they are $8.84, $6.37 and $3.18.

Quantity tiers take 3 %, 5 % or 10 % off the list price separately, which puts the best published tier at $89.99 a vial, or $9.00 per labelled milligram. That is two and a half times the code price, so the tiers are not the lever they look like on a compound with a single SKU. Free shipping starts at $250.

The order to run these checks in is the reverse of the order most buyers use. Certificate, then identity, then testing scope, then dispatch, then arithmetic. Only the last step has a number in it, and the first three decide whether that number describes anything. If you want the arithmetic in isolation, our price page runs it across every price point and quantity tier.